Analytical Cellular Pathology / 2019 / Article / Fig 3

Research Article

Acylated Ghrelin Renders Chemosensitive Ovarian Cancer Cells Resistant to Cisplatin Chemotherapy via Activation of the PI3K/Akt/mTOR Survival Pathway

Figure 3

Acylated ghrelin (AG) activates the PI3K/Akt signaling pathway in control and cisplatin- (Cis-) treated cultured human chemosensitive ovarian cancer cells (A2780). Cells were grown in DMEM/F12 media containing AG ghrelin (1 nM) for 24 hours, then transferred to a medium containing the vehicle for the next 72 hours. For Cis treatment, cells were grown in the same medium containing Cis (10 μM) for 72 hours. In addition, AG and Cis-treated cells were also preincubated with 10 μM ghrelin receptor antagonist, [D-Lys3]-GHRP-6, and/or 20 μM of the PI3K inhibitor, LY294002. Control cells were grown in the presence equivalent volume of normal saline. Results are shown as the of experiments. a: vs control (lane 1), b: vs AG (lane 2), c: vs AG+LY294002 (lane 3), d: vs Cis (lane 4), e: vs AG+Cis (lane 5). Lane 6: Cis+AG+LY294002 and lane 7: Cis+AG+[D-Lys3]-GHRP-6.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.